Publications
Ovarian cancer - angiogenesis and targeted therapy Vrije Universiteit Brussel
Epithelial ovarian cancer (EOC) is the leading cause of death from gynecologic malignancies in developed countries. Despite advances in chemotherapy leading to improved outcomes in EOC, mortality rates have marginally decreased, because most patients will develop resistance to standard chemotherapy. New anti-tumor agents with novel mechanisms of action are needed. Angiogenesis is one of the regulated processes that are crucial for tumor ...
Activation of invariant natural killer T cells reduces angiogenesis in the 5T33 multiple myeloma model Vrije Universiteit Brussel
Nur H1,2, Rao L3, Vacca A3, , Elewaut D4, Van Valckenborgh E1, De Bruyne E1, Vanderkerken K1 and Menu E1
1 Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium.
2 Department of Biology, Hebron University, Hebron, Palestine.
3 Department of Biomedical ...
JunB is a key regulator of multiple myeloma bone marrow angiogenesis Vrije Universiteit Brussel
Bone marrow (BM) angiogenesis significantly influences disease progression in multiple myeloma (MM) patients and correlates with adverse prognosis. The present study shows a statistically significant correlation of the AP-1 family member JunB with VEGF, VEGFB, and IGF1 expression levels in MM. In contrast to the angiogenic master regulator Hif-1α, JunB protein levels were independent of hypoxia. Results in tumor-cell models that allow the ...
The pivotal role of angiogenesis in a multi-scale modeling of tumor growth exhibiting the avascular and vascular phases Ghent University
Chorioallantoic Membrane Assay as Model for Angiogenesis in Tissue Engineering: Focus on Stem Cells Hasselt University Ghent University
Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers Vrije Universiteit Brussel
Solid cancers are dependent on angiogenesis for sustenance. The FDA approval of Bevacizumab in 2004 inspired many scientists to develop more inhibitors of angiogenesis. Although several monoclonal antibodies (mAbs) are being administered to successfully combat various pathologies, the complexity and large size of mAbs seem to narrow the therapeutic applications. To improve the performance of cancer therapeutics, including those blocking tumor ...
Stimulation of invariant natural killer T cells by α-Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model Vrije Universiteit Brussel
Circulating endothelial cells as a biomarker for angiogenesis in cancer: where do we stand? Vrije Universiteit Brussel
Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPinprotein MP0250 Vrije Universiteit Brussel
The investigational drug MP0250 is a multi-specific DARPin®molecule that simultaneously binds and neutralizes VEGF and HGF with high specificity and affinity. Here we studied the antiangiogenic effects of the MP0250 in multiple myeloma (MM). In endothelial cells (EC) isolated from bone marrow (BM) of MM patients (MMEC) MP0250 reduces VEGFR2 and cMet phosphorylation and affects their downstream signaling cascades. MP0250 influences the ...